Market Currents
Abbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of...
-
Tuesday, June 5, 2012, 10:23 AM ETAbbott Labs (ABT) and Neurocrine Biosciences (NBIX) are starting a 24-week Phase III trial of elagolix, a treatment for endometriosis, which is a debilitating gynecological disease that affects around 100M women worldwide and can cause infertility. (PR)
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
